An expert from Case Western Reserve University explains how cancer cells survive treatment, why rare diseases are hard to study and why CAR-T therapy offers hope.
An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.
An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.
Vicki McGrath, a Bay Area Cancer Connections board member, talks about fatigue, fear of movement and the role of peer support in post-surgery exercise.
At its 23rd annual conference, Bay Area Cancer Connections described how donations and volunteers fund services for people facing cancer’s medical, financial and practical costs.
On World Pancreatic Cancer Day, here are five numbers from the American Cancer Society's 2026 report that people with pancreatic cancer and their families should understand, and what those numbers can and cannot say about one person's outlook.
Rasonque (daraxonrasib), the first approved drug to directly target RAS in pancreatic cancer, nearly doubled survival in a key trial. Two patients, a caregiver and the professionals who care for people like them explain what it means to live with the disease.